Over the past six months, Eli Lilly’s stock price fell to $872.91. Shareholders have lost 8.3% of their capital, which is disappointing considering the S&P 500 has climbed by 8.9%. This might have investors contemplating their next move.

Following the drawdown, is now the time to buy LLY? Find out in our full research report, it’s free.

Why Are We Positive On Eli Lilly?

Founded in 1876, Eli Lilly (NYSE:LLY) is a global pharmaceutical company that develops and produces a wide range of medicines and vaccines for medical conditions such as diabetes, cancer, and mental health disorders.

1. Long-Term Revenue Growth Shows Strong Momentum

A company’s long-term sales performance signals its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, Eli Lilly grew its sales at a solid 15.1% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.

2. Outstanding Long-Term EPS Growth

We track the long-term change in earnings per share (EPS) because it highlights whether a company’s growth is profitable.

Eli Lilly’s EPS grew at an astounding 17.7% compounded annual growth rate over the last five years, higher than its 15.1% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

3. Stellar ROIC Showcases Lucrative Growth Opportunities

Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).

Eli Lilly’s five-year average ROIC was 27.3%, placing it among the best healthcare companies. This illustrates its management team’s ability to invest in highly profitable ventures and produce tangible results for shareholders.

Final Judgment

These are just a few reasons why we think Eli Lilly is one of the best healthcare companies out there. After the recent drawdown, the stock trades at 36.3× forward price-to-earnings (or $872.91 per share). Is now a good time to buy? See for yourself in our in-depth research report, it’s free.

Stocks We Like Even More Than Eli Lilly

The elections are now behind us. With rates dropping and inflation cooling, many analysts expect a breakout market - and we’re zeroing in on the stocks that could benefit immensely.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.

Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free.